Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium

Keyphrases

• Meta-analysis 100%
• Gene Signature 100%
• Airway Epithelium 100%
• COVID-19 100%
• Drug Repurposing 100%
• Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 100%
• Induced Genes 100%
• Existing Drugs 37%
• Drug Target 25%
• Ranking Algorithm 25%
• CXCL10 25%
• Ingenuity Pathway Analysis 25%
• Viral 12%
• Clinical Trials 12%
• Illness 12%
• CXCL1 12%
• Gene Network 12%
• Associated Proteins 12%
• Differentially Expressed Genes 12%
• Inflammatory Pathways 12%
• FDA-approved Drugs 12%
• Repurposing 12%
• Signature-based 12%
• Biomarker Development 12%
• Pathway Network 12%
• CCL20 12%
• CLC Genomics Workbench 12%
• Canonical Pathway 12%
• Primary Human Airway Epithelial Cells 12%
• RNA-sequencing Data 12%
• Novel Gene Signatures 12%
• CXCL8 12%
• Effective Interventions 12%

Biochemistry, Genetics and Molecular Biology

• Gene Signature 100%
• SARS-related Coronavirus 100%
• CXCL10 50%
• RNA Sequence 25%
• SEQUEST 25%
• Clinical Trial 25%
• Drug Screening 25%
• Gene Network 25%
• CCL20 25%
• Genomics 25%
• CXCL1 25%
• Differentially Expressed Gene 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Drug Repositioning 100%
• SARS-related Coronavirus 100%
• Biological Marker 25%
• Clinical Trial 25%
• Infection 25%
• Antivirus Agent 25%
• Repurposing 25%
• Drug Screening 25%
• Diseases 25%
• Pathogenesis 25%